

Survival of Patients with Neuroendocrine Tumors in Ontario over last 15 years

Authors: Simron Singh*, Moises Cukier*, Refik Saskin**, Ning Liu** and Calvin Law*
*Sunnybrook Odette Cancer Centre, University of Toronto
**Institute for Clinical Evaluative Sciences (ICES), Canada



Background

- Increasing incidence of neuro-endocrine tumors (NETs) have been shown worldwide
- Recent data has confirmed a greater than 2x increase in NETs incidence from 1994-2009 in the province of Ontario, Canada (pop of approx 13 million people)
- Little is known about trends in survival or factors associated with survival during this period among this population

Objective

- To examine survival and associated prognostic factors of NETs patients in Ontario, Canada from 1994-2009

Methods

- A population based study was initiated using the Ontario Cancer Registry (OCR), cross-linked with the Registered Persons Database and the Canadian Institute of Health Information (CIHI) Discharge Abstract Database
- All NETs diagnosed between January 1994 and December 2009 were collected using ICD-9 diagnostic codes and ICD-O histology codes
- Baseline demographic, clinical and outcomes data were abstracted
- Overall Survival (OS) was calculated using Kaplan-Meier methodology and comparison between the groups was performed with long-rank test
- A multivariate model using Cox proportional-hazards regression was employed to test for factors independently associated with survival

Results

- A total of N=5619 cases were identified
- The 5-y OS among age groups: ≤ 50 (79%), 51-60 (67%), 61-70 (59%) and ≥ 71 (39%) [p < 0.0001]
- 5-year OS was compared for patients with and without metastatic disease after diagnosis (69.0% vs 40.1%, p<0.0001)

Table 1: Probability of Recurrence-free Survival (RFS) and overall survival (OS)

	RFS	OS
One Year	0.81	0.81
Five Year	0.71	0.61
Ten Year	0.65	0.47

Figure 2: Overall survival of NET patients with adjustment for age by sex




Figure 1: Age-adjusted Overall Survival of NETs patients, by cancer primary site.




Figure 3: Multivariate analysis of survival (Cox proportion model)

Variable	Hazard Ratio (95% CI)	p value
Male	1.296 (1.188-1.415)	<.0001
Age	1.042 (1.038-1.045)	<.0001
Income quintile (ref=5 th)		
1	1.249 (1.093-1.428)	0.0011
2	1.088 (0.949-1.247)	0.2244
3	0.983 (0.856-1.127)	0.8016
4	1.088 (0.949-1.249)	0.2265
Cancer recurrence	1.901 (1.737-2.082)	<.0001
Rural resident	1.129 (1.000-1.275)	0.0499
Primary site (ref=Bronchus, Lung)		
Small Intestine	0.587 (0.507-0.679)	<.0001
Rectum	0.343 (0.269-0.437)	<.0001
Large Intestine	0.940 (0.807-1.093)	0.4197
Pancreas	1.396 (1.198-1.627)	<.0001
Stomach	0.819 (0.653-1.028)	0.0848

Discussion

- Survival among NETs patients decreases over time with less than 50% survival at 10 years
- Poor outcome factors include male sex, age of diagnosis, pancreatic primary, rural status and low income quintile
- The decreased survival among male patients is poorly understood and needs to be explored further
- It is possible that rural residence and low income may be related to decreased access to health care resources and possibly delayed diagnosis or sub-optimal treatments in this uncommon malignancy

Conclusion

- Survival appears to vary significantly according to anatomical site along with some demographic and socioeconomic factors
- Efforts should be made to promote awareness of this disease and to offer access to specialized health care for NET patients living in remote areas